Literature DB >> 18779413

A mechanism for the HLA-A*01-associated risk for EBV+ Hodgkin lymphoma and infectious mononucleosis.

Rebekah M Brennan, Scott R Burrows.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18779413     DOI： 10.1182/blood-2008-06-162883

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  13 in total

1.  HLA*IMP--an integrated framework for imputing classical HLA alleles from SNP genotypes.

Authors:  Alexander T Dilthey; Loukas Moutsianas; Stephen Leslie; Gil McVean
Journal:  Bioinformatics       Date:  2011-02-07       Impact factor: 6.937

2.  Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients.

Authors:  R Reshef; M R Luskin; M Kamoun; S Vardhanabhuti; J E Tomaszewski; E A Stadtmauer; D L Porter; D F Heitjan; De E Tsai
Journal:  Am J Transplant       Date:  2011-03-14       Impact factor: 8.086

3.  HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma.

Authors:  Henrik Hjalgrim; Klaus Rostgaard; Paul C D Johnson; Annette Lake; Lesley Shield; Ann-Margaret Little; Karin Ekstrom-Smedby; Hans-Olov Adami; Bengt Glimelius; Stephen Hamilton-Dutoit; Eleanor Kane; G Malcolm Taylor; Alex McConnachie; Lars P Ryder; Christer Sundstrom; Paal Skytt Andersen; Ellen T Chang; Freda E Alexander; Mads Melbye; Ruth F Jarrett
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

4.  Phased whole-genome genetic risk in a family quartet using a major allele reference sequence.

Authors:  Frederick E Dewey; Rong Chen; Sergio P Cordero; Kelly E Ormond; Colleen Caleshu; Konrad J Karczewski; Michelle Whirl-Carrillo; Matthew T Wheeler; Joel T Dudley; Jake K Byrnes; Omar E Cornejo; Joshua W Knowles; Mark Woon; Katrin Sangkuhl; Li Gong; Caroline F Thorn; Joan M Hebert; Emidio Capriotti; Sean P David; Aleksandra Pavlovic; Anne West; Joseph V Thakuria; Madeleine P Ball; Alexander W Zaranek; Heidi L Rehm; George M Church; John S West; Carlos D Bustamante; Michael Snyder; Russ B Altman; Teri E Klein; Atul J Butte; Euan A Ashley
Journal:  PLoS Genet       Date:  2011-09-15       Impact factor: 5.917

5.  HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China.

Authors:  Xin Huang; Bouke Hepkema; Ilja Nolte; Kushi Kushekhar; Theo Jongsma; Rianne Veenstra; Sibrand Poppema; Zifen Gao; Lydia Visser; Arjan Diepstra; Anke van den Berg
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

6.  The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.

Authors:  K Jones; L Wockner; R M Brennan; C Keane; P K Chattopadhyay; M Roederer; D A Price; D K Cole; B Hassan; K Beck; D Gottlieb; D S Ritchie; J F Seymour; F Vari; P Crooks; S R Burrows; M K Gandhi
Journal:  Clin Exp Immunol       Date:  2015-11-13       Impact factor: 4.330

7.  Carcinogenesis of nasopharyngeal carcinoma: an alternate hypothetical mechanism.

Authors:  Sharon Shuxian Poh; Melvin Lee Kiang Chua; Joseph T S Wee
Journal:  Chin J Cancer       Date:  2016-01-06

8.  Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes.

Authors:  Maren Bieling; Sabine Tischer; Ulrich Kalinke; Rainer Blasczyk; Søren Buus; Britta Maecker-Kolhoff; Britta Eiz-Vesper
Journal:  Oncotarget       Date:  2017-12-21

9.  Epstein-Barr Virus and the Human Leukocyte Antigen Complex.

Authors:  Qingxue Li; Jeffrey I Cohen
Journal:  Curr Clin Microbiol Rep       Date:  2019-07-08

10.  Proteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infection.

Authors:  Calum Forrest; Andrew D Hislop; Alan B Rickinson; Jianmin Zuo
Journal:  PLoS Pathog       Date:  2018-09-24       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.